Research Analysts Offer Predictions for VVOS Q1 Earnings

Vivos Therapeutics, Inc. (NASDAQ:VVOS) – Ascendiant Capital Markets raised their Q1 2026 earnings estimates for shares of Vivos Therapeutics in a research note issued on Wednesday, April 22nd. Ascendiant Capital Markets analyst L. Ward now expects that the company will post earnings of ($0.40) per share for the quarter, up from their previous forecast of ($0.45). Ascendiant Capital Markets currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Vivos Therapeutics’ current full-year earnings is ($1.45) per share. Ascendiant Capital Markets also issued estimates for Vivos Therapeutics’ Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.34) EPS and FY2026 earnings at ($1.48) EPS.

VVOS has been the subject of a number of other reports. HC Wainwright cut their price objective on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a research report on Friday, April 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $2.58.

Vivos Therapeutics Stock Performance

NASDAQ VVOS opened at $0.86 on Tuesday. The stock has a market capitalization of $11.64 million, a price-to-earnings ratio of -0.42 and a beta of 6.93. The stock has a 50-day moving average of $1.27 and a 200 day moving average of $1.87. The company has a current ratio of 0.24, a quick ratio of 0.24 and a debt-to-equity ratio of 3.31. Vivos Therapeutics has a twelve month low of $0.81 and a twelve month high of $7.95.

Vivos Therapeutics (NASDAQ:VVOS) last posted its earnings results on Wednesday, April 15th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.08). Vivos Therapeutics had a negative return on equity of 849.22% and a negative net margin of 121.37%.The firm had revenue of $3.82 million for the quarter, compared to analysts’ expectations of $7.10 million. During the same period in the previous year, the company earned ($2.22) earnings per share.

Insider Activity

In other news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the stock in a transaction dated Tuesday, March 31st. The shares were purchased at an average cost of $1.34 per share, with a total value of $1,813,857.50. Following the completion of the purchase, the insider directly owned 1,353,625 shares of the company’s stock, valued at approximately $1,813,857.50. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 2.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in Vivos Therapeutics during the 2nd quarter worth $65,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Vivos Therapeutics during the second quarter worth $220,000. Connective Capital Management LLC acquired a new stake in shares of Vivos Therapeutics in the third quarter valued at about $620,000. Acorn Wealth Advisors LLC acquired a new stake in shares of Vivos Therapeutics in the fourth quarter valued at about $30,000. Finally, DRW Securities LLC lifted its stake in shares of Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after buying an additional 74,441 shares in the last quarter. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.